Attendee search 

Cro

Illumina is a provider of Next Generation Sequencing technology

专注医疗投资

Oncology Big Data company headquartered in Beijing. Chinese name 神州医疗 or Digital Health China. US branch in Boston.

Brilliant was founded in Chengdu city in 2007, specializes in the manufacturing and sale of generic medicines, innovative biologicals, small molecules and inhaled preparations. The sales revenue in 2019 was nearly US $550 million. We have 5 R&D centers and 5 GMP factories.

High-throughput Human Disease and Tissue Models

MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.

CTS Capital was founded in 2017. As a private equity firm, CTS Capital focuses on investment opportunities in the biotechnology and healthcare services industries. CTS Capital is managed by a team of professionals with deep industry knowledge, extensive experiences in private equity and global strategic insights. Driven by our team’s business acumen and investment expertise, CTS Capital has made investments in companies at the cutting edge of the biotechnology and healthcare industries, including innovative drugs, medical devices, diagnostics, gene technology, digital health and AI in healthcare，etc.
We employ a research-driven investment approach and collaborate closely with our companies to build lasting and impactful businesses in the life sciences and healthcare industries. We are committed to working in close partnership with the top innovative pharmaceutical, biotech and medical technology companies to promote biotechnology innovation and healthcare transformation in China.